5 Biggest Blockbuster Drugs of the Future
Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.
Bristol-Myers Squibb
BMY
BMY
$47.68
$0.35
0.0%
BATS BZX Real Time Price as of June 14, 2019, 3:38 p.m.
View Interactive BMY Charts
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
News & Analysis: Bristol-Myers Squibb
The Fool has written over 1000 articles on Bristol-Myers Squibb.
Top 5 Stocks in the Fight Against Cancer
These stocks are leading the way in their respective areas in battling cancer.
10 Jaw-Dropping Numbers About Cancer Drug Development -- and What They Mean for Investors
There's more good news with the fight against cancer than you might think.
How Often Is Buying Into a Stock Market Correction a Bad Idea?
You'll be surprised by the answer.
Here's Why Nektar Therapeutics Is Soaring Today
Promising data suggest the company might be able to raise the bar in melanoma treatments.
This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy
And the analyst really likes one in particular.
3 Stocks Peter Lynch Would Love
They could be big winners for patient investors.
Bristol-Myers Squibb Co (BMY) Q1 2019 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2019.
Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming
The big drugmaker beat Wall Street estimates in the first quarter thanks to solid sales growth for its top blockbusters.
Kidney-Cancer Market: Good for Patients, Hard for Investors
Drugmakers battle for patients.
